Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.32 |
| ▸ | PRCP | P42785 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782813 | 0.93 | HCRTR1 (0.32) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL10121580 | 0.90 | PRCP (0.37) | HCRTR1HCRTR2PRCP | |
| SCHEMBL18782914 | 0.87 | HCRTR1 (0.34) | HCRTR1HCRTR2PRCPGRM5 | |
| SCHEMBL18782993 | 0.85 | HCRTR1 (0.36) | HCRTR1HCRTR2PRCP | |
| SCHEMBL10121598 | 0.84 | GABRA1 (0.32) | PRCPGRM5 | |
| SCHEMBL18782818 | 0.83 | — | — | |
| SCHEMBL22361400 | 0.83 | HCRTR1 (0.40) | HCRTR1HCRTR2PRCP | |
| SCHEMBL18782958 | 0.82 | HCRTR1 (0.31) | HCRTR1HCRTR2PRCP | |
| SCHEMBL19364716 | 0.82 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL10121596 | 0.82 | PRCP (0.36) | HCRTR1HCRTR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | HCRTR1 4466/4885HCRTR2 4679/4885PRCP 1337/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | HCRTR1 4412/4885HCRTR2 4631/4885PRCP 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.